Two Doses, One Molecule

A companion to What the Label Cannot Say and The Store That Sells the Right. Those pieces described the legal and commercial architecture that keeps the substrate off the label and marks up what does reach the shelf. This one addresses the argumentative gesture, older than either, that keeps the two categories of dose separate in the first place.

The received distinction

There is a form of authoritative common sense, deployed most often against orthomolecular practice, that runs as follows. The vitamin at the recommended daily allowance is a nutrient. The vitamin at ten, fifty, or five hundred times that dose is a different thing. The dose changes everything. The molecule at one concentration belongs to nutrition; at another it belongs to pharmacology; at another still, to fringe experimentation. A person who takes vitamin C at the RDA is participating in an accepted practice. A person who takes three grams a day is doing something that requires a different vocabulary, a different scrutiny, and by implication a different license.

The gesture is not without weight. Dose does matter. Toxicity ceilings are real. There are substances that are nutrients at low intakes and hazards at high ones: selenium, retinol, iron, and vitamin D among them. No serious argument against the distinction ignores this.

What the argument objects to is the way the distinction is deployed. The observer who says “the dose changes everything” almost never says it symmetrically. They say it to disqualify a subject taking a nutrient at a repletion dose in the absence of clinical oversight. They do not say it when the same nutrient is administered at the same or higher dose inside a hospital. That asymmetry is the load-bearing part of the argument, and it is worth examining directly.

What the hospital does with its own vitamins

Consider the doses medicine itself uses when it has decided the situation calls for them.

Vitamin B12. The recommended daily allowance is 2.4 micrograms. The standard protocol for confirmed B12 deficiency is 1000 micrograms by intramuscular injection, daily for a week, then weekly for a month, then monthly for life. That is roughly four hundred times the RDA, delivered by needle. No physician regards this as a departure from vitamin practice. It is the vitamin, at the repletion rate.

Folate. The RDA is 400 micrograms. Megaloblastic anemia is treated with 1 to 5 milligrams of folic acid daily. Between two and twelve times the RDA, orally, indefinitely. In the pregnant woman with a prior neural-tube-defect pregnancy, 4 to 5 milligrams daily is standard prophylaxis.

Thiamine. The RDA is 1.2 milligrams. Wernicke’s encephalopathy is treated with 500 milligrams intravenously three times daily for two days, then 250 milligrams daily. That is more than a thousand times the RDA, at the tempo the situation calls for.

Magnesium. The oral RDA is around 400 milligrams. Eclampsia is treated with a 4 to 6 gram intravenous loading dose of magnesium sulfate followed by 1 to 2 grams per hour. The obstetrician does not pause to observe that this is a suspiciously “megadose” of a mineral otherwise found in food.

Vitamin D. The RDA is 600 to 800 IU. The standard repletion regimen for severe deficiency is 50,000 IU weekly for eight to twelve weeks. That is roughly sixty times the daily RDA every seven days.

Vitamin K. The RDA is 90 to 120 micrograms. Emergency reversal of warfarin-induced coagulopathy uses 10 milligrams intravenously. About a hundred times the RDA.

Potassium. The adequate intake is around 3.4 grams. Hospital replacement for hypokalemia routinely delivers 40 to 60 milliequivalents (about 1.5 to 2.3 grams of elemental potassium) per infusion, often repeated, with oral loading of comparable magnitude across the day. Correction of a chronically depleted subject can require these amounts for many days before tissue reserves begin to catch up.

Iron. The RDA is 8 to 18 milligrams. Intravenous iron sucrose delivers 200 milligrams per session; ferric carboxymaltose can deliver 500 to 1000 milligrams in a single infusion. Ten to a hundred times the RDA, bypassing intestinal absorption entirely.

None of these regimes is called “megavitamin therapy” or “supra-physiological dosing” inside the hospital. They are called treatment. The vocabulary of orthomolecular deviance is reserved for the subject who arrives at the same conclusion outside the clinical setting and administers the same molecule to themselves.

The distinction that is supposed to change everything, then, does not track the dose. It tracks the hand.

Two problems, two rates

The point of this catalogue is not that medicine is a model to imitate. It is that medicine is an invitation to look more closely. Its own protocols demonstrate what its own rhetoric denies: that the RDA and the repletion dose are answers to two different physiological questions, and that any serious framework has to distinguish them.

The RDA is a prevention target. Its explicit design intent is to describe the intake that will prevent frank deficiency in the eugenic subject who has always had that intake. It is not calibrated to restore the subject who is now depleted. It says nothing about the tissue stores of the person who has been under-replete for years, nor about the person whose losses are elevated by physiological load, medication, or condition.

The repletion dose is a restoration target. Its design intent is to bring a depleted subject back to functional adequacy on a timescale that outpaces ongoing losses. Medicine acknowledges this in every one of the regimes listed above. It sets the dose to the compartment that has been drained, not to the RDA that was calibrated for a subject who was never drained.

The uninformed observer conflates the two. They read the RDA as a ceiling and any dose above it as suspicious. The physician quietly ignores the RDA as a treatment guide because it was never designed to be one. The observer’s error is not corrected in public, because the correction would grant to the ambulatory patient the same conceptual permission the hospital already uses in private.

The asymmetry that requires the higher dose

The physiological reason medicine has to reach for these doses is not incidental. It follows from a general asymmetry that runs through almost every micronutrient and every conditionally essential substrate.

It is easier to lose a molecule than to regain it.

Loss and gain are not symmetric processes in the human body. They differ by architecture, by rate, and by the number of upstream conditions each requires. The asymmetry has at least six components, each of which matters on its own and all of which compound.

Loss channels are not saturable. The kidney can dump potassium indefinitely under diuretic pressure or aldosterone signaling. Sweat can shed magnesium and sodium for as long as the exertion continues. Vomiting, diarrhea, and nasogastric aspiration can lose electrolytes at multiple liters per day. Medication-induced wasting is chronic and invisible: proton pump inhibitors and B12, metformin and B12, loop diuretics and magnesium, potassium and thiamine, isoniazid and B6, colchicine and B12 again. Oxidative stress consumes glutathione in seconds. Chronic inflammation and catabolic states consume substrate faster than eugenic intake supplies it. None of these loss channels pause to check the repletion status of the subject. They operate on their own logic.

Gain channels are transporter-limited. Absorption is metered. Iron is absorbed at roughly 1 to 2 milligrams per day in the healthy adult once the intestine has downregulated in response to sufficiency. Magnesium’s fractional absorption drops from around 65 percent at low intake to around 11 percent at high intake. B12 absorption via intrinsic factor saturates at roughly 1.5 to 2 micrograms per meal; anything above that must cross by passive diffusion, which is why oral B12 repletion works only at doses in the milligrams. Calcium and zinc absorb by saturable transporters. Fat-soluble vitamins depend on bile flow and intact enterocyte function. The gate that admits the molecule is narrow. The gate that lets it leave is not.

Plasma restores faster than tissue. The serum compartment is small and rapidly buffered. The intracellular and tissue compartments are large and slow to refill. This is the point on which this resource has insisted from the beginning: a normalized serum potassium after intravenous replacement does not mean the myocardium is repleted; it means the plasma has caught up with the infusion. Magnesium is the paradigm case. Serum magnesium can return to reference range within hours of a bolus while intracellular and skeletal reserves remain depleted for weeks or months of continued supplementation. The subject who has been depleted for years does not become physiologically adequate at the moment the serum test reads normal. See Magnesium and Potassium for the case histories that made this point unforgettable.

Deficits reinforce each other. The substrates form loops in which the depletion of one accelerates the loss of another. Magnesium deficit impairs the ROMK channel’s ability to retain potassium; a hypomagnesemic subject cannot correct hypokalemia until the magnesium is restored. Vitamin D deficit impairs magnesium absorption. Folate and B12 depletion each disrupts the one-carbon metabolism that regenerates the other. Glutathione synthesis fails without cysteine, glycine, glutamate, and ATP, each of which requires nutrient cofactors upstream. Repletion often has to correct several substrates simultaneously to escape the loop. Half-corrections stall or backslide.

Adaptive downregulation slows the return. Chronic deficit remodels the physiology in ways that persist after intake resumes. Transporter density adjusts. Storage capacity contracts. Enzyme expression shifts. These adjustments are not instantly reversible. The body that has learned to live at the low set-point does not immediately resume operation at the higher one when supply returns. Some fraction of the repletion window is spent re-expressing the apparatus that will use the substrate once it is again available.

Time-integrated damage may not fully reverse. Deficits sustained long enough leave structural residues: myocardial remodeling from chronic hypokalemia, mitochondrial dysfunction from chronic B-vitamin deficit, methylation-pattern disturbances from chronic folate insufficiency, arterial calcification from vitamin K insufficiency compounded by isolated vitamin D excess without K co-repletion. Some of these residues remit with time and adequate substrate. Some do not. The subject who reaches the RDA after twenty years below it is not the subject who was always at the RDA.

Taken together, these features describe a physiological system whose losses are unmetered and whose gains are metered, whose plasma restores quickly and whose tissues restore slowly, whose deficits reinforce each other, and whose remodeling outlasts the substrate that caused it. This is why the repletion rate must exceed the RDA. Not by fiat of hospital protocol, but because the arithmetic of loss and gain requires it.

The time factor

The corollary that medicine’s own protocols make plain is that the tempo of intake matters as much as the amount. Dose is a rate: milligrams per day, sustained across the days the situation requires. A restoration attempted at RDA-equivalent tempo may never overtake ongoing losses in a subject whose loss channels are elevated. Medicine’s high-dose loading regimens are not expressions of enthusiasm. They are expressions of the recognition that a slow re-fill against a fast drain does not converge.

This is what “the dose changes everything” gets right and gets wrong at the same time. The dose does change the outcome, because the outcome is a function of dose multiplied by time integrated against loss. But the molecule is not different at the higher dose. The problem is different. The prevention problem has one arithmetic. The repletion problem has another. Confusing the two, in either direction, leads to error. The observer who insists on the RDA as a repletion ceiling is making the same category error as the observer who would supplement recreationally with pharmacological doses of a fat-soluble vitamin.

The rhetorical move

The received distinction, then, functions less as physiology than as a gatekeeping device. Its practical effect is to concede pharmacological doses to the medical profession while denying them to the subject who has arrived at the same reasoning outside the profession. When medicine gives 1000 micrograms of B12 by injection, it is treating a deficiency. When the ambulatory subject takes 1000 micrograms of B12 orally for their own deficiency, they are engaged in “self-medication with megadoses” and the received view furrows its brow.

The molecule does not know who is holding the syringe. The physiology does not distinguish between the two subjects. The distinction is administrative.

Recognizing this is not a call to substitute the ambulatory subject for the clinician. Where the clinician exists and is willing to test, read the test against a threshold of function rather than a population mean, and support restoration, the subject is better served in that relationship. Where the clinician does not order the test, or reads it against a lax threshold, or declines to support restoration, the ambulatory subject faces the same physiology the hospital would face, and the same arithmetic of loss and gain, at doses the RDA does not describe. The right of informed self-medication covers this ground. What this piece adds is that the doses required to exercise that right are not, by their magnitude alone, an argument against it.

What the framework has to include

A right that ends at the recommended daily allowance is a right to prevention among the never-depleted. It is not a right to restoration. It is the right this resource has argued, throughout, is insufficient: the right of the person who was never in the deficit, protected from a state they would not have entered anyway.

The right this resource argues for extends further. It includes the right to be brought back to the substrate levels compatible with normal function when one has fallen below them. That right presupposes acknowledgment of the asymmetry that governs return. Because loss is easier than regain, because the RDA does not restore, because tissue restoration is slow, because deficits reinforce each other, because damage integrates, restoration will in most cases require doses and durations that the received view of “eat well” or “a multivitamin covers it” cannot supply.

Medicine already knows this. Its own protocols admit it every time a syringe is drawn. The task of the framework this resource defends is to name the asymmetry openly, to attach the right of restoration to the physiology that requires it, and to retire the argumentative device by which the same dose becomes acceptable or dangerous depending on the hand that administers it.